NDATOPICALCREAM
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VANIQA (eflornithine hydrochloride) by AbbVie is clinical pharmacology. First approved in 2000.
Drug data last refreshed 3h ago · AI intelligence enriched 3h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANIQA (eflornithine HCl) is a topical cream approved in 2000 that inhibits ornithine decarboxylase to reduce facial hair growth in women. It is indicated for unwanted facial hair and works by slowing hair growth rather than removing existing hair. The mechanism targets polyamine synthesis in hair follicles.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling a mature-to-declining team structure focused on retention rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VANIQA offers limited career growth due to its approaching loss of exclusivity and minimal linked job opportunities (0 current openings). This role is better suited for professionals seeking stability in a mature, niche product or gaining experience in a LOE transition environment before moving to growth-stage pipeline products.
Brand ManagerField Sales Representative
Worked on VANIQA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.